MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
The University of Texas MD Anderson Cancer Center and Myriad Genetics have announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.
This collaboration combines Myriad’s oncology diagnostic expertise with MD Anderson’s clinical research capabilities to create a portfolio of studies evaluating the clinical validity and utility of Myriad’s Precise MRD test. The studies will focus on breast, gastrointestinal, genitourinary, and gynecological cancers.
Myriad's Chief Scientific Officer, Dale Muzzey, emphasized the potential of the Precise MRD test to enhance treatment strategies by detecting tumor-derived DNA at very low levels, which could improve patient outcomes.
Under the agreement, MD Anderson will handle patient enrollment, sample collection, clinical data analysis, and manuscript writing, while Myriad will provide funding, MRD testing, and scientific research support, along with potential milestone and royalty payments.
MD Anderson's Christopher Flowers highlighted the alliance's goal to explore MRD testing applications, including relapse monitoring, identifying high-risk patients, and potential intervention approaches.
Il Centro Diagnostico per il Cancro MD Anderson dell'Università del Texas e Myriad Genetics hanno annunciato un'alleanza strategica di cinque anni per accelerare la valutazione clinica e lo sviluppo del test per la malattia residua molecolare (MRD) di Myriad.
Questa collaborazione unisce l'esperienza diagnostica oncologica di Myriad con le capacità di ricerca clinica di MD Anderson, per creare un portafoglio di studi volti a valutare la validità clinica e l'utilità del test Precise MRD di Myriad. Gli studi si concentreranno su tumori mammari, gastrointestinali, genitourinari e ginecologici.
Il Chief Scientific Officer di Myriad, Dale Muzzey, ha sottolineato il potenziale del test Precise MRD di migliorare le strategie di trattamento rilevando il DNA derivato da tumori a livelli molto bassi, il che potrebbe migliorare gli esiti per i pazienti.
Secondo l'accordo, MD Anderson si occuperà dell'arruolamento dei pazienti, della raccolta dei campioni, dell'analisi dei dati clinici e della scrittura dei manoscritti, mentre Myriad fornirà finanziamenti, test MRD e supporto alla ricerca scientifica, insieme a potenziali pagamenti per traguardi e diritti d'autore.
Christopher Flowers di MD Anderson ha evidenziato l'obiettivo dell'alleanza di esplorare le applicazioni del test MRD, inclusi il monitoraggio delle recidive, l'identificazione di pazienti ad alto rischio e potenziali approcci all'intervento.
El Centro de Cáncer MD Anderson de la Universidad de Texas y Myriad Genetics han anunciado una alianza estratégica de cinco años para acelerar la evaluación clínica y el desarrollo del ensayo de enfermedad residual molecular (MRD) de Myriad.
Esta colaboración combina la experiencia diagnóstica oncológica de Myriad con las capacidades de investigación clínica de MD Anderson, para crear un portafolio de estudios destinados a evaluar la validez clínica y la utilidad de la prueba MRD Precise de Myriad. Los estudios se centrarán en cánceres de mama, gastrointestinales, genitourinarios y ginecológicos.
El Director Científico de Myriad, Dale Muzzey, enfatizó el potencial de la prueba MRD Precise para mejorar las estrategias de tratamiento al detectar ADN derivado de tumores a niveles muy bajos, lo que podría mejorar los resultados en los pacientes.
En virtud del acuerdo, MD Anderson se encargará de la inscripción de pacientes, la recolección de muestras, el análisis de datos clínicos y la redacción de manuscritos, mientras que Myriad proporcionará financiación, pruebas de MRD y apoyo a la investigación científica, junto con posibles pagos por hitos y regalías.
Christopher Flowers de MD Anderson destacó el objetivo de la alianza de explorar aplicaciones de pruebas MRD, incluyendo el monitoreo de recaídas, la identificación de pacientes de alto riesgo y posibles enfoques de intervención.
텍사스 대학교 MD 앤더슨 암 센터와 Myriad Genetics는 Myriad의 분자 잔여 질병(MRD) 테스트의 임상 평가 및 개발을 가속화하기 위한 5년 전략적 동맹을 발표했습니다.
이번 협력은 Myriad의 종양학 진단 전문성과 MD 앤더슨의 임상 연구 능력을 결합하여 Myriad의 Precise MRD 테스트의 임상 유효성과 유용성을 평가하는 연구 포트폴리오를 만들고자 합니다. 연구는 유방암, 위장관암, 비뇨생식기 암 및 부인과 암에 중점을 둘 것입니다.
Myriad의 최고 과학 책임자인 Dale Muzzey는 Precise MRD 테스트가 매우 낮은 수준에서 종양 유래 DNA를 탐지하여 치료 전략을 개선할 수 있는 잠재력이 있다고 강조하며, 이를 통해 환자 결과를 향상시킬 수 있다고 말했습니다.
합의에 따라 MD 앤더슨은 환자 등록, 샘플 수집, 임상 데이터 분석 및 원고 작성을 담당하며, Myriad는 자금 지원, MRD 테스트 및 과학 연구 지원을 제공하고 이정표 및 로열티 지급 가능성도 제시합니다.
MD 앤더슨의 Christopher Flowers는 이번 동맹의 목표가 MRD 테스트의 적용을 탐색하는 것으로, 재발 모니터링, 고위험 환자 식별 및 잠재적 개입 접근 방식을 포함한다고 강조했습니다.
Le Centre de Cancérologie MD Anderson de l'Université du Texas et Myriad Genetics ont annoncé une alliance stratégique de cinq ans pour accélérer l'évaluation clinique et le développement du test de maladie résiduelle moléculaire (MRD) de Myriad.
Cette collaboration allie l'expertise diagnostique en oncologie de Myriad aux capacités de recherche clinique de MD Anderson pour créer un portefeuille d'études évaluant la validité et l'utilité clinique du test Precise MRD de Myriad. Les études se concentreront sur les cancers du sein, gastro-intestinaux, génito-urinaires et gynécologiques.
Le Directeur Scientifique de Myriad, Dale Muzzey, a souligné le potentiel du test Precise MRD pour améliorer les stratégies thérapeutiques en détectant l'ADN tumoral à des niveaux très bas, ce qui pourrait améliorer les résultats pour les patients.
Dans le cadre de l'accord, MD Anderson s'occupera de l'inscription des patients, de la collecte des échantillons, de l'analyse des données cliniques et de la rédaction des manuscrits, tandis que Myriad fournira des financements, des tests MRD et un soutien à la recherche scientifique, ainsi que des paiements potentiels pour des jalons et des redevances.
Christopher Flowers de MD Anderson a souligné que l'objectif de l'alliance est d'explorer les applications des tests MRD, y compris la surveillance des rechutes, l'identification des patients à haut risque et les approches d'intervention potentielles.
Das MD Anderson Cancer Center der Universität Texas und Myriad Genetics haben eine fünfjährige strategische Allianz angekündigt, um die klinische Evaluierung und Entwicklung des Molekulartests für die residuale Erkrankung (MRD) von Myriad zu beschleunigen.
Diese Zusammenarbeit kombiniert Myriads Expertise in der Onkologie-Diagnostik mit den klinischen Forschungsfähigkeiten von MD Anderson, um ein Portfolio an Studien zu erstellen, die die klinische Validität und Nützlichkeit von Myriads Precise MRD-Test bewerten. Die Studien konzentrieren sich auf Brust-, Magen-Darm-, urogenitale und gynäkologische Krebserkrankungen.
Myriads Chief Scientific Officer, Dale Muzzey, betonte das Potenzial des Precise MRD-Tests, Behandlungsstrategien durch die Erkennung von tumordériviertem DNA auf sehr niedrigen Niveaus zu verbessern, was die Ergebnisse für die Patienten verbessern könnte.
Gemäß der Vereinbarung wird MD Anderson die Patientenaufnahme, Probenentnahme, klinische Datenanalyse und Manuskripterstellung übernehmen, während Myriad Funding, MRD-Tests und wissenschaftliche Forschungsunterstützung bereitstellt, sowie mögliche Meilenstein- und Lizenzgebührenzahlungen.
Christopher Flowers von MD Anderson hob das Ziel der Allianz hervor, Anwendungen des MRD-Tests zu erkunden, darunter Rückfallüberwachung, Identifizierung von Hochrisikopatienten und potenzielle Interventionsansätze.
- Strategic alliance with MD Anderson enhances Myriad's clinical research capabilities.
- Potential for Precise MRD test to improve cancer treatment strategies.
- Studies aim to support national guideline inclusion and healthcare provider adoption.
- Collaboration includes funding, potential milestone, and royalty payments from Myriad.
- None.
Insights
The strategic alliance between MD Anderson and Myriad Genetics represents a pivotal development in cancer diagnostics and treatment monitoring. The collaboration's focus on Precise MRD's ultrasensitive detection capabilities (detecting tumor DNA at significantly lower levels than first-generation tests) could revolutionize how cancer progression and treatment response are monitored.
The study portfolio spanning breast, gastrointestinal, genitourinary and gynecological cancers is particularly comprehensive. The dual approach of retrospective and prospective studies strengthens the potential for robust clinical validation. If successful, inclusion in national guidelines would significantly expand Myriad's market presence in the rapidly growing <money>$5.8 billion</money> global MRD testing market.
Put simply: Think of MRD testing as a highly sensitive smoke detector for cancer - it can detect even the smallest traces of cancer cells remaining after treatment, potentially allowing doctors to adjust treatment plans much earlier than current methods allow.
This alliance has substantial commercial implications for Myriad Genetics. The partnership with MD Anderson, a top-tier cancer center, provides significant validation potential for Precise MRD. The milestone and royalty payment structure suggests confidence in the technology's commercial viability.
The agreement's structure is particularly favorable - while Myriad provides funding and testing support, successful outcomes could lead to expanded market access through guideline inclusion, potentially driving substantial revenue growth. The global MRD testing market is projected to grow at a <percent>12.5%</percent> CAGR through 2030, representing a significant growth opportunity.
In everyday terms: This is like getting a seal of approval from one of the world's most respected cancer centers - if the studies succeed, it could help Myriad capture a larger share of a rapidly growing market, potentially boosting their revenue significantly in the coming years.
HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad’s Precise MRD.
“We look forward to working with MD Anderson to evaluate Precise MRD’s utility in cancer care,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “Our collaborative studies will explore how our ultrasensitive Precise MRD test can enhance treatment strategies for providers and improve patient outcomes. We are optimistic that our MRD test’s ability to quantitatively detect tumor-derived DNA at very low levels — far lower than is possible with first-generation MRD tests — will open new opportunities for therapy-response and recurrence monitoring.”
Under the terms of the agreement, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers. The goal of these studies is to generate evidence that supports national guideline inclusion and healthcare provider adoption. MD Anderson investigators will lead patient enrollment, sample collection, clinical data analysis and manuscript writing. Myriad will provide funding, MRD testing and scientific research support as well as potential milestone and royalty payments under the collaboration.
“This strategic alliance brings together cutting-edge technology and expertise from Myriad with disease-focused expertise and clinical trials excellence from MD Anderson,” said Christopher Flowers, M.D., division head of Cancer Medicine at MD Anderson. “We aim to explore numerous applications for MRD testing, including monitoring patients for relapse after treatment, identifying high-risk patients in need of clinical trials, and potentially intervention approaches.”
The alliance expands upon existing collaborations between MD Anderson researchers and Myriad, including ongoing studies in breast cancer and renal cell carcinoma.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit Myriad.com.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that Myriad will work with MD Anderson to evaluate Precise MRD’s utility in cancer care, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies to investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers, the collaborative studies will explore how the Precise MRD test can enhance treatment strategies for providers and improve patient outcomes, and Myriad’s belief that its MRD test’s ability to quantitatively detect tumor-derived DNA at very low levels will open new opportunities for therapy-response and recurrence monitoring. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
What is the significance of the MYGN and MD Anderson alliance?
What cancers will the MYGN MRD test studies focus on?
What roles will MD Anderson and Myriad Genetics play in the alliance?
What potential benefits does the MYGN Precise MRD test offer?
What are the goals of the MYGN and MD Anderson studies?
What financial aspects are involved in the MYGN and MD Anderson collaboration?
